{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:10:53Z","timestamp":1794345053083,"version":"4.9.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>RGI-2001, a glycolipid that binds CD1d receptor of antigen-presenting cells, can activate invariant natural killer T (NKT) cells and stimulate cytokine-dependent proliferation of regulatory T cells (Tregs). This open-label, multicenter phase 2b trial evaluated the safety and efficacy of RGI-2001 in combination with standard graft-versus-host disease (GVHD) prophylaxis in participants receiving myeloablative allogeneic hematopoietic cell transplantation (HCT). RGI-2001 was infused at a dose of 100 \u03bcg\/kg for 6 weekly doses. The primary end point was grade 2 to 4 acute GVHD by day 100. A total of 49 participants received RGI-2001 in combination with tacrolimus and methotrexate. RGI-2001 was well tolerated, with no serious infusion reactions. Sixteen participants experienced grade \u22653 treatment-related adverse events, including decreased appetite, leukopenia, thrombocytopenia, and stomatitis. The cumulative incidence of grade 2 to 4 and 3 to 4 acute GVHD were 24.9% and 4.1%, respectively. Compared with the controls from the Center for International Blood and Marrow Research Transplant registry, participants receiving RGI-2001 experienced superior clinical outcomes, including day-180 grade 2 to 4 acute GVHD-free survival (70.8% vs 50.7%; adjusted hazard ratio, 0.45; 95% confidence interval, 0.30-0.68). Increasing NKT and Treg populations were observed after HCT, consistent with the proposed action of RGI-2001. In conclusion, RGI-2001 was well tolerated and was associated with low rates of acute GVHD and encouraging survival after myeloablative HCT. These results support strategies that target NKT and Treg cell populations to augment immunologic changes in allogeneic HCT recipients. This trial was registered at www.clinicaltrials.gov as #NCT04014790.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029584","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T20:38:02Z","timestamp":1752871082000},"page":"2037-2046","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"first","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-2989","authenticated-orcid":false,"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-8823","authenticated-orcid":false,"given":"Yvonne A.","family":"Efebera","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Blood and Marrow Transplant, OhioHealth, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0130","authenticated-orcid":false,"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[{"name":"4Division of Acute Leukemia, College of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-7442","authenticated-orcid":false,"given":"Shatha","family":"Farhan","sequence":"additional","affiliation":[{"name":"5Division of Hematology Oncology, Department of Internal Medicine, Henry Ford Health, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2077-7032","authenticated-orcid":false,"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[{"name":"6Division of Transplantation and Cellular Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-6299","authenticated-orcid":false,"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"7Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8547-8905","authenticated-orcid":false,"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology, Columbia University Irving Medical Center\/NewYork-Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-9265","authenticated-orcid":false,"given":"Amer","family":"Assal","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-3652","authenticated-orcid":false,"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[{"name":"11Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-368X","authenticated-orcid":false,"given":"Jack D.","family":"Bui","sequence":"additional","affiliation":[{"name":"12Department of Pathology, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Lee","sequence":"additional","affiliation":[{"name":"13Department of Clinical Development, REGiMMUNE Corporation, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Lane","sequence":"additional","affiliation":[{"name":"13Department of Clinical Development, REGiMMUNE Corporation, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2025102311220703000_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2025102311220703000_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2025102311220703000_bib3","first-page":"844.e1","article-title":"Late effects of severe acute graft-versus-host disease on quality of life, medical comorbidities, and survival","volume":"28","author":"Rashid","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"22","key":"2025102311220703000_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"2025102311220703000_bib5","doi-asserted-by":"crossref","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD Prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"issue":"25","key":"2025102311220703000_bib6","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102311220703000_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025102311220703000_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","article-title":"ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"2025102311220703000_bib9","first-page":"576.e1","article-title":"Phase II study of myeloablative 7-8\/8-matched allotransplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"29","author":"Jurdi","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"17","key":"2025102311220703000_bib10","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025102311220703000_bib11","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"issue":"18","key":"2025102311220703000_bib12","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.2024026446","article-title":"Donor regulatory T-cell therapy to prevent graft-versus-host disease","volume":"145","author":"Meyer","year":"2025","journal-title":"Blood"},{"key":"2025102311220703000_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"2025102311220703000_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nri1531","article-title":"Alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles","volume":"5","author":"Van Kaer","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"2025102311220703000_bib15","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1182\/blood-2008-06-165506","article-title":"Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease","volume":"113","author":"Pillai","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2025102311220703000_bib16","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2013-08-453126","article-title":"Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation","volume":"122","author":"Schneidawind","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2025102311220703000_bib17","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","article-title":"CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells","volume":"124","author":"Schneidawind","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2025102311220703000_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2017.01.069","article-title":"Increased Foxp3(+)Helios(+) regulatory T cells and decreased acute graft-versus-host disease after allogeneic bone marrow transplantation in patients receiving sirolimus and rgi-2001, an activator of invariant natural killer T cells","volume":"23","author":"Chen","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2025102311220703000_bib19","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2025102311220703000_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2025102311220703000_bib21","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2025102311220703000_bib22","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bbmt.2010.11.022","article-title":"Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models","volume":"17","author":"Duramad","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025102311220703000_bib23","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1038\/s41598-021-92526-z","article-title":"Reduced dose of PTCy followed by adjuvant alpha-galactosylceramide enhances GVL effect without sacrificing GVHD suppression","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"2025102311220703000_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/iid3.425","article-title":"Donor Treg expansion by liposomal alpha-galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft-versus-host disease","volume":"9","author":"Sugiura","year":"2021","journal-title":"Immun Inflamm Dis"},{"issue":"3","key":"2025102311220703000_bib25","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025102311220703000_bib26","author":"Meyer","year":"30 -2  2025"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/17\/2037\/2417547\/blood_bld-2025-029584-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/17\/2037\/2417547\/blood_bld-2025-029584-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T15:22:17Z","timestamp":1761232937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/17\/2037\/546275\/RGI-2001-for-the-prophylaxis-of-acute-graft-versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,10,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029584","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,23]]},"published":{"date-parts":[[2025,10,23]]}}}